Early Treatment of ARNI on Myocardial Remodeling and Progress
Status:
Not yet recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
Myocardial remodeling following myocardial infarction (MI) is an important prognostic factor
for heart function and adverse cardiovascular events, especially are intimately linked with
heart failure. MI often causes deleterious changes in ventricular size, shape, and function.
This adverse remodeling and progress is mediated by neurohormonal and hemodynamic
alterations. The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan was
shown to be superior to an ACE inhibitor in patients with heart failure with reduced ejection
fraction (HF-REF), reduce the risk of both death (from cardiovascular and all-causes) and
heart failure hospitalization, may be a new approach to the treatment of heart failure.
However, the impact of early treatment of ARNI on myocardial remodeling and progress, and
aerobic exercise capacity in patients with prior MI has yet to be assessed. The aim of this
study is to evaluate the efficacy and the safety of early treatment of ARNI on myocardial
remodeling and progress, and aerobic exercise capacity in patients following MI.